BioSpace News Archive

The OpenFold group, a non-profit artificial intelligence research consortium of biotech and tech firms whose goal is to develop free and open-source software tools for biology and drug discovery, is announcing the funding of new large-scale protein studies at Prof. Gabriel Rocklin’s laboratory at Northwestern University.

Shoulder Innovations Inc., a Grand Rapids, Michigan based leader in the shoulder replacement implant market announced that they have hired Mr. Jeff Points as Chief Financial Officer.

Immunexpress, Pty Ltd. announced a poster presentation demonstrating the usefulness of SeptiCyte® RAPID in conjunction with clinical assessment of sepsis for informing on antibiotic administration and bundle compliance at the annual meeting of the American College of Chest Physicians.

MEI Pharma, Inc. announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances.

AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.

Eledon Pharmaceuticals, Inc. announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.

uniQure N.V. announced the grant of inducement equity awards to newly hired employees.

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announced a shakeup of the management of its Vietnamese subsidiary, Prodigy Textiles.

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced new data demonstrating the significant clinical utility of its TissueCypher® Barrett’s Esophagus test in guiding risk-aligned upstaging of care for patients with non-dysplastic Barrett’s esophagus (NDBE) at a higher risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) than indicated by their clinicopathologic risk factors.